Key result
Chromium picolinate improves β-cell function, pancreatic histology, and vascular markers in diabetic rats.
Why the study?
The effect of chromium picolinate supplementation on pancreatic function and macroangiopathy in type II diabetes mellitus was not well understood.
Does chromium picolinate supplementation improve pancreatic function and alleviate macroangiopathy in a rat model of type II diabetes mellitus?
RCT (n=50)
Randomly divided
Does chromium picolinate supplementation improve pancreatic function and alleviate macroangiopathy in a rat model of type II diabetes mellitus?
Chromium picolinate supplementation recovers beta-cell function and alleviates macroangiopathy in a rat model of type II diabetes.
PURPOSE: The aim was to explore the effect of the chromium picolinate (CrPic) administration on the pancreas and macroangiopathy of type II diabetes mellitus rats. METHODS: The type II diabetes mellitus (T2DM) rat model was induced by low-dose streptozotocin (STZ). The rats were randomly divided into 5 groups (ten rats in each group). After supplementing CrPic for 15 weeks, the histopathological examination was performed by hematoxylin-eosin (HE) staining. Serum insulin and NO level were determined by radioimmunoassay and colorimetry, respectively. Serum glycosylated hemoglobin (HbA1C), adiponectin (APN), advanced glycation end products (AGES), and apelin were measured by ELISA. Real-time reverse transcription polymerase chain reaction (RT-PCR) was applied for detecting the mRNA expression of APN and apelin. RESULTS: After CrPic treatment, compared with the T2DM control group (group 2), pancreas sections stained with HE showed the completed pancreatic cells structure and no inflammatory infiltration in groups 4 and 5. In addition, the levels of serum NO and insulin were significantly increased and the serum levels of HbA1C, AGES, APN, and apelin were significantly decreased in groups 4 and 5 compared with group 2. The mRNA expression of APN and apelin in groups 4 and 5 was also recovered to the normal level. CONCLUSION: CrPic can recover the function of Β-cells and alleviate macroangiopathy in STZ-induced T2DM rats.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2014) conducted an RCT in Type II diabetes mellitus (n=50). Chromium picolinate (CrPic) vs. T2DM control group was evaluated on Pancreas histopathology and serum levels of insulin, NO, HbA1C, APN, AGES, and apelin. Chromium picolinate supplementation for 15 weeks recovered β-cell function, improved pancreatic structure, and alleviated macroangiopathy markers in STZ-induced type II diabetes mellitus rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: